Abstract: Disclosed are compounds of formula (I): in which L1, L2, LD1, LD2, R5, and R6 are defined. Also provided are pharmaceutical compositions containing such a compound a method of treating cancer using the compound.

Abstract: Pyrimidine compounds of formula (I) shown herein. Also disclosed are pharmaceutical compositions containing one of the pyrimidine compounds and methods of using the pyrimidine compounds to treat or prevent chemotherapy-induced peripheral neuropathy.

Abstract: A control device, a control signal generation method and a voltage conversion device are provided. A delay circuit generates a delay signal based on a power signal. An output end of a logic circuit outputs a third level voltage in response to that the power signal or the battery signal is at a second level voltage. The output end outputs a fourth level voltage in response to that the power signal and the battery signal both are at a first level voltage. In response to that an output signal of the output end is the third level voltage, an output circuit outputs a level voltage of the received power signal when the delay signal is changed from the first level voltage to the second level voltage. The output circuit outputs a stopping voltage in response to that the output signal of the logic circuit is the fourth level voltage.

Abstract: Pyrimidine compounds of formula (I) shown herein. Also disclosed are pharmaceutical compositions containing one of the pyrimidine compounds and methods of using the pyrimidine compounds to treat or prevent chemotherapy-induced peripheral neuropathy.

Abstract: A method for assessment of neural function by establishing an analysis module is revealed. The first step of the method is to capture images of the cultured cells with a plurality of fluorescence labeling by a fluorescence microscopy system for image analysis. The cultured cells include neurons and non-neuronal cells. Then select neurons with neurites having fluorescence labeling and exclude non-neuronal cells according to an area and a fluorescence intensity of nucleus. Also calculate an area of the neuronal cell body, a length of the neurites and a number of processes and branches to verify outgrowth of the neurites of the neurons. Next calculate a number of synaptic puncta having fluorescence labeling on the area of the neurites having fluorescence labeling defined in Step 2 to verify formation of the synaptic puncta of the neurons for assessment of neural function.

Abstract: Fused bicycle indol, indoline, azoindole, or azoindoline compounds of Formula (I) set forth herein. Also disclosed are pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing the same. Further disclosed is a method for treating cancer, e.g., glioma, prostate cancer, and colorectal cancer, with these compounds.

Abstract: The present invention is to provide a docking station applicable to a portable electronic device and having an anti-theft mechanism, which includes a positioning base having a top side concavely provided with a positioning space and a first abutting surface provided adjacent to one end of the positioning base and facing the positioning space; a sliding base movably connected to an opposite end of the positioning base and provided with a second abutting surface facing the positioning space, wherein the first and second abutting surfaces are respectively and protrudingly provided with a first plug and a second plug configured to be inserted into and thereby connected with corresponding sockets of the portable electronic device; a first fastener and a second fastener respectively provided at the sliding base and the positioning base and capable of being fastened together to prevent the sliding base from moving with respect to the positioning base.

Abstract: Fused bicycle indol, indoline, azoindole, or azoindoline compounds of Formula (I) set forth herein. Also disclosed are pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing the same. Further disclosed is a method for treating cancer, e.g., glioma, prostate cancer, and colorectal cancer, with these compounds.

Abstract: A method for assessment of neural function by establishing an analysis module is revealed. The first step of the method is to capture images of the cultured cells with a plurality of fluorescence labeling by a fluorescence microscopy system for image analysis. The cultured cells include neurons and non-neuronal cells. Then select neurons with neurites having fluorescence labeling and exclude non-neuronal cells according to an area and a fluorescence intensity of nucleus. Also calculate an area of the neuronal cell body, a length of the neurites and a number of processes and branches to verify outgrowth of the neurites of the neurons. Next calculate a number of synaptic puncta having fluorescence labeling on the area of the neurites having fluorescence labeling defined in Step 2 to verify formation of the synaptic puncta of the neurons for assessment of neural function.

Abstract: A level shift circuit includes a level shift module and a voltage comparing module. The level shift module includes a plurality of stages of level shift units, each including a front-end circuit and an inverter circuit. The inverter circuit is electrically coupled to the front-end circuit and receives and inverts an output signal of the front-end circuit. The front-end circuit receives a clock signal, converts high/low voltage level of the clock signal into first/second voltage level, respectively, and outputs a respective signal with the first/second voltage level. The voltage comparing module is coupled to the level shift module and receives output signals of the inverter circuit of the first level shift unit and of the front-end circuit in the second level shift unit and compares the two output signals. The voltage comparing module outputs a short-circuit protection trigger signal when the two output signals have different voltages.

Abstract: A level shift circuit includes a level shift module and a voltage comparing module. The level shift module includes a plurality of stages of level shift units, each including a front-end circuit and an inverter circuit. The inverter circuit is electrically coupled to the front-end circuit and receives and inverts an output signal of the front-end circuit. The front-end circuit receives a clock signal, converts high/low voltage level of the clock signal into first/second voltage level, respectively, and outputs a respective signal with the first/second voltage level. The voltage comparing module is coupled to the level shift module and receives output signals of the inverter circuit of the first level shift unit and of the front-end circuit in the second level shift unit and compares the two output signals. The voltage comparing module outputs a short-circuit protection trigger signal when the two output signals have different voltages.

Abstract: Cathepsin S inhibitors having formula (I), (II), (III) or (IV) as shown in the specification. These inhibitors can be used to treat cancer and autoimmune/inflammatory diseases.

Abstract: Aryl substituted sulfonamide compounds of formula (I): wherein bond, X, Y, R1, R2, R3, m, and n are defined herein. Also disclosed is a method for treating cancer with these compounds.

Abstract: Coumarin compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, and X are defined herein. Also disclosed is a method for treating cancer with coumarin compounds.

Abstract: A serious of nitro heterocyclic derivatives including a structure of formula (I) are provided. In formula (I), P, Q and R1 to R8 are defined in the specification. The derivatives disclosed in the present invention are characterized in inhibiting tubulin polymerization, and treating cancers and other tubulin polymerization-related disorders with a suitable pharmaceutical acceptable carrier.

Abstract: Cathepsin S inhibitors having formula (I), (II), (III) or (IV) as shown in the specification. These inhibitors can be used to treat cancer and autoimmune/inflammatory diseases.

Abstract: Aryl substituted sulfonamide compounds of formula (I): wherein bond, X, Y, R1, R2, R3, m, and n are defined herein. Also disclosed is a method for treating cancer with these compounds.

Abstract: A series of indoline-sulfonamide compounds is disclosed. The formula of indoline-sulfonamide compounds is shown as formula (I). In formula (I), R1 is H or halogen; R2 is Ar, Ar—C(O)—, Ar—CH2—, Ar—SO2—, Ar—O—C(O), or R?—C(O)—, and Ar is a substituted or unsubstituted C5-C20 aryl, cyclyl, heterocyclyl, or heteroaryl, R? and R? independently is C1-C10 alkyl, or C1-C10 alkoxyl; and R3 is C5-C15 aryl or C1-C10 alkyl. The indoline-sulfonamide compounds disclosed in the present invention are characterized in inhibiting tubulin polymerization, and treating cancers and other tubulin polymerization-related disorders with a suitable pharmaceutical acceptable carrier.

Abstract: A diffusion plate assembly includes a diffusion plate made from transparent material. Pluralities of bar-type patterns are disposed on the emission surface of the diffusion plate. The outline of these patterns has a first curve and a second curve. The protruding direction of the first curve and the second curve are inversed. The second curve is an arc whose radius curvature is between 0.05 mm and 0.3 mm.

Abstract: Coumarin compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, and X are defined herein. Also disclosed is a method for treating cancer with coumarin compounds.